Cargando…

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

OBJECTIVE: Clinical trials have recently shown a connection between nonalcoholic fatty liver disease (NAFLD) and empagliflozin. This paper aimed at comprehensively assessing the effectiveness and security of empagliflozin in NAFLD patients. METHODS: PubMed, Embase, Web of Science, Cochrane Library,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuyuan, Liu, Xiaobo, Zhang, Huazhu, Wang, Xuechang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908261/ https://www.ncbi.nlm.nih.gov/pubmed/35282455 http://dx.doi.org/10.3389/fendo.2022.836455

Ejemplares similares

Lean nonalcoholic fatty liver disease and sarcopenia
por: Chen, Milian, et al.
Publicado: (2023)

Role of extracellular vesicles in nonalcoholic fatty liver disease
por: Jiang, Wei, et al.
Publicado: (2023)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
por: Niu, Shu, et al.
Publicado: (2023)

The impact of obstructive sleep apnea on nonalcoholic fatty liver disease
por: Tang, Haiying, et al.
Publicado: (2023)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Publicado: (2023)

Correlation of Adiponectin Gene Polymorphisms rs266729 and rs3774261 With Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zheng, Yong-Tian, et al.
Publicado: (2022)

Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease
por: Jiang, Yuanye, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease in University Rugby Football Players
por: Nirengi, Shinsuke, et al.
Publicado: (2018)

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2022)

The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Ndakotsu, Andrew, et al.
Publicado: (2022)

The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose–response meta-analysis
por: Ling, Qin, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhu, Yuan, et al.
Publicado: (2021)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
por: Zhou, Fangli, et al.
Publicado: (2021)

Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
por: Tsankof, Alexandra, et al.
Publicado: (2022)

Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
por: Friesen, Chance S., et al.
Publicado: (2021)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2023)

The efficacy and safety of acupuncture in nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
por: Chen, Peiwen, et al.
Publicado: (2021)

Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
por: Lyu, Jingting, et al.
Publicado: (2022)

Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity
por: Zhou, Xuelian, et al.
Publicado: (2022)

Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms
por: Takahashi, Hirokazu, et al.
Publicado: (2018)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease
por: Zhao, Yanhua, et al.
Publicado: (2022)

Red Blood Cell Count: An Unrecognized Risk Factor for Nonalcoholic Fatty Liver Disease
por: Zhong, Fang, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies
por: Albhaisi, Somaya, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
por: Yu, Yuetian, et al.
Publicado: (2023)

The efficacy of Qigong exercises for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis
por: Liu, Yuqiao, et al.
Publicado: (2020)

Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
por: He, Weiwei, et al.
Publicado: (2017)

Efficacy and safety of Yinchenwuling Powder for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis of randomized controlled trials
por: Wu, Peishan, et al.
Publicado: (2022)

Serum IL-27 levels increase in subjects with hypothyroidism and are negatively correlated with the occurrence of nonalcoholic fatty liver disease
por: Wen, Yahui, et al.
Publicado: (2023)

The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
por: Pokharel, Arbinda, et al.
Publicado: (2021)

Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2021)

Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis
por: Ren, Mengting, et al.
Publicado: (2022)

Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis
por: Zhang, Qin, et al.
Publicado: (2023)

Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: A study of human and animals
por: Chen, Li, et al.
Publicado: (2023)

Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index
por: Chen, Xueyu, et al.
Publicado: (2022)

Causal effects of nonalcoholic fatty liver disease on cerebral cortical structure: a Mendelian randomization analysis
por: Mai, Zhiliang, et al.
Publicado: (2023)

Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis
por: Shi, Xiao-yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tiadr7ng6llpmlkmaap3v8h1jb